To clinically develop this WT1 oral cancer vaccine, we generated a recombinant B. longum 440 displaying a partial human WT1 protein (aa117–419), and produced B440, a pharmaceutical formulation of the lyophilized powder of inactivated B. longum 440.25 This evidence concerns the gene WT1 and lip and oral cavity carcinoma.